市場調査レポート
商品コード
1333995

造影超音波の世界市場 (~2028年):製品 (機器・ナノ粒子&分子標的マイクロバブル・ソフトウェア)・用途・エンドユーザー・地域別

Contrast Enhanced Ultrasound Market by Product (Equipment, Nanoparticle & Molecule-targeted Microbubbles, Software), Application, End User & Region - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 172 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
造影超音波の世界市場 (~2028年):製品 (機器・ナノ粒子&分子標的マイクロバブル・ソフトウェア)・用途・エンドユーザー・地域別
出版日: 2023年08月07日
発行: MarketsandMarkets
ページ情報: 英文 172 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の造影超音波の市場規模は、2023年の16億米ドルから、予測期間中は6.1%のCAGRで推移し、2028年には21億米ドルの規模に成長すると予測されています。

老年人口の増加や造影剤の使用の増加などの要因が同市場の成長を推進していますまた、R&D活動の増加、政府のイニシアティブ、臨床試験件数の増加も市場成長に寄与しています。

製品別で見ると、機器の部門が2022年に最大のシェアを示しています。同部門の大きなシェアは、先進技術によるシステムの発売とエンドユーザーによる造影超音波システムの使用の増加によるものです。用途別では、治療の部門が予測期間中に最大のCAGRを示す見通しです。標的ドラッグデリバリーや患者モニタリングのための造影剤使用の増加などの要因が市場成長を促進しています。

地域別では、アジア太平洋地域が予測期間中、最大の成長を示す見通しです。同地域は、進化するヘルスケアインフラと同地域の主要企業による注力の拡大により、最大の成長を示す見通しです。中国やインドなどの新興国のヘルスケアインフラは急速なペースで進化しており、病院や診断センターによる高度な画像診断システムへの大規模な投資につながっています。

当レポートでは、世界の造影超音波の市場を調査し、市場概要、市場影響因子および市場機会の分析、技術・特許の動向、ケーススタディ、関連法規制、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • ポーターのファイブフォース分析
  • 貿易分析
  • 特許分析
  • 親市場のエコシステムの範囲
  • バリューチェーン分析
  • サプライチェーン分析
  • 価格傾向分析
  • 技術分析
  • 規制状況
  • 償還シナリオ
  • ケーススタディ
  • 主要な会議とイベント

第6章 造影超音波市場:製品・サービス別

  • 機器
  • 造影剤
    • 分子標的マイクロバブル
    • ナノ粒子マイクロバブル
  • ソフトウェア・サービス

第7章 造影超音波市場:用途別

  • 診断
    • 心臓病
    • 肝臓
    • 腎臓
    • その他
  • 治療
    • 心臓病
    • 血管
    • 腫瘍
    • その他

第8章 造影超音波市場:エンドユーザー別

  • 病院・外科センター
  • 画像診断センター
  • 外来手術センター
  • その他

第9章 造影超音波市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 概要
  • 主要企業の採用戦略
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • 競合ベンチマーキング
  • 競合シナリオと動向

第11章 企業プロファイル

  • 主要企業
    • GE HEALTHCARE
    • LANTHEUS
    • BRACCO IMAGING S.P.A.
    • KONINKLIJKE PHILIPS N.V.
    • SIEMENS HEALTHINEERS
    • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • CANON INC.
    • ESAOTE S.P.A
    • SAMSUNG ELECTRONICS CO., LTD.
    • GUERBET
  • その他の企業
    • NANOPET PHARMA GMBH
    • BAYER AG
    • REVVITY
    • SOLSTICE PHARMACEUTICALS B.V.
    • TRIVITRON HEALTHCARE
    • LERIVA
    • JB PHARMA

第12章 付録

目次
Product Code: MD 8748

The global contrast-enhanced ultrasound market is projected to reach USD 2.1 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 6.1% from 2023 to 2028. Factors such as rising geriatric population and increasing use of contrast agents are responsible for the increasing growth of this market. Increasing research and development activities, government initiatives, and the rising number of clinical trials also contribute to the growth of the contrast-enhanced ultrasound market.

"The equipment segment held the largest share of the market in 2022."

Based on equipment, the contrast-enhanced ultrasound market is segmented into equipment, contrast agents, and software and services. The contrast-enhanced ultrasound equipment segment held the largest market share in 2022. The large share of this segment can be attributed to the launch of technologically advanced systems and the rising use of contrast-enhanced ultrasound systems by end users.

"The therapeutic applications segment is projected to register the highest CAGR during the forecast period."

Based on application, the contrast-enhanced ultrasound market is segmented into diagnostic applications and therapeutic applications. The therapeutic application segment is projected to register the highest CAGR from 2023 to 2028. Factors such as the increasing use of contrast agents for targeted drug delivery and patient monitoring are driving market growth.

"The market in the Asia Pacific region is expected to witness the highest growth during the forecast period."

The contrast-enhanced ultrasound market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and the increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India, is evolving at a rapid pace, leading to major investments in advanced imaging systems by hospitals and diagnostic centers. These factors are anticipated to fuel the growth of the contrast-enhanced ultrasound market in this region.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
  • By Designation: C-level-10%, Director-level-14%, and Others-76%
  • By Region: North America-40%, Europe-32%, Asia Pacific-20%, Rest of the World-8%

The prominent players in the contrast-enhanced ultrasound market are GE Healthcare (US), Lantheus Holdings, Inc. (US), Bracco Imaging SpA (Italy), and Koninklijke Philips N.V. (Netherlands), among others.

Research Coverage

This report studies the contrast-enhanced ultrasound market based on product, application, end-user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall contrast-enhanced ultrasound market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (growing prevalence of chronic diseases, technological advancements, and rising partnerships and collaborations between market players), restraints (side effects of contrast agents), opportunities (growth opportunities in emerging countries and rising number of hospitals and diagnostic imaging centers), and challenges (shortage of skilled sonographers and presence of alternative techniques) influencing the growth of the contrast-enhanced ultrasound market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the contrast-enhanced ultrasound market
  • Market Development: Comprehensive information about lucrative markets-the report analyses the contrast-enhanced ultrasound market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the contrast-enhanced ultrasound market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like GE Healthcare (US), Lantheus Holdings, Inc. (US), Bracco Imaging SpA (Italy), Koninklijke Philips N.V. (Netherlands), Siemens Healthcare GmbH (Germany), Shenzen Mindary Bio-Medical Electronics Co, Ltd. (China).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SEGMENTATION
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES
  • 1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 CONTRAST-ENHANCED ULTRASOUND MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY RESEARCH
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 MARKET SIZE ESTIMATION FOR CONTRAST-ENHANCED ULTRASOUND MARKET: APPROACH 1 (COMPANY REVENUE ESTIMATION)
    • FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF GE HEALTHCARE
      • 2.2.1.2 Approach 2: Customer-based market estimation
    • FIGURE 7 BOTTOM-UP APPROACH FOR MARKET SIZE ESTIMATION
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET ASSUMPTIONS
  • 2.5 RISK ASSESSMENT
    • 2.5.1 RISK ASSESSMENT ANALYSIS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 10 CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CONTRAST-ENHANCED ULTRASOUND MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 CONTRAST-ENHANCED ULTRASOUND MARKET OVERVIEW
    • FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • 4.2 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
    • FIGURE 15 CONTRAST AGENTS SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • 4.3 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2023 VS. 2028
    • FIGURE 16 THERAPEUTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER
    • FIGURE 17 HOSPITALS AND SURGICAL CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.5 CONTRAST-ENHANCED ULTRASOUND MARKET: GEOGRAPHICAL SNAPSHOT
    • FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 CONTRAST-ENHANCED ULTRASOUND MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of chronic diseases
      • 5.2.1.2 Rising technological advancements in contrast-enhanced ultrasound systems
      • 5.2.1.3 Increasing initiatives for commercialization of diagnostic imaging equipment
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Risks associated with contrast agents
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
      • 5.2.3.2 Increasing establishment of hospitals and diagnostic imaging centers
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled sonographers
      • 5.2.4.2 Presence of alternative techniques
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 1 CONTRAST-ENHANCED ULTRASOUND MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 TRADE ANALYSIS
    • TABLE 2 IMPORT DATA FOR ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2022 (USD THOUSAND)
    • TABLE 3 EXPORT DATA FOR ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2022 (USD THOUSAND)
    • TABLE 4 IMPORT DATA FOR CONTRAST AGENTS, BY COUNTRY, 2018-2022 (USD THOUSAND)
    • TABLE 5 EXPORT DATA FOR CONTRAST AGENTS, BY COUNTRY, 2018-2022 (USD THOUSAND)
  • 5.5 PATENT ANALYSIS
    • FIGURE 20 TOP 10 PATENT APPLICANTS (JANUARY 2012-DECEMBER 2022)
  • 5.6 ECOSYSTEM COVERAGE OF PARENT MARKET
  • 5.7 VALUE CHAIN ANALYSIS
    • 5.7.1 RESEARCH & DEVELOPMENT
    • 5.7.2 MANUFACTURING & ASSEMBLY
    • 5.7.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
    • FIGURE 21 VALUE CHAIN ANALYSIS
  • 5.8 SUPPLY CHAIN ANALYSIS
    • 5.8.1 PROMINENT COMPANIES
    • 5.8.2 SMALL & MEDIUM-SIZED ENTERPRISES
    • 5.8.3 END USERS
    • FIGURE 22 SUPPLY CHAIN ANALYSIS
  • 5.9 PRICING TREND ANALYSIS
    • TABLE 6 AVERAGE SELLING PRICE FOR MAJOR CONTRAST-ENHANCED ULTRASOUND EQUIPMENT
  • 5.10 TECHNOLOGY ANALYSIS
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 NORTH AMERICA
      • 5.11.1.1 US
    • TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.11.1.2 Canada
    • TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
    • 5.11.2 EUROPE
    • 5.11.3 ASIA PACIFIC
      • 5.11.3.1 Japan
    • TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
      • 5.11.3.2 China
    • TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
      • 5.11.3.3 India
  • 5.12 REIMBURSEMENT SCENARIO
    • TABLE 12 MEDICAL REIMBURSEMENT CODES FOR CONTRAST-ENHANCED ULTRASOUND PROCEDURES
  • 5.13 CASE STUDIES
    • 5.13.1 TECHNICAL CHALLENGES WITH ULTRASOUND SYSTEMS
    • TABLE 13 CASE STUDY 1: IMPROVED SENSITIVITY AND BETTER VISIBILITY OF BLOOD FLOW
  • 5.14 KEY CONFERENCES AND EVENTS
    • TABLE 14 CONTRAST-ENHANCED ULTRASOUND MARKET: LIST OF MAJOR CONFERENCES AND EVENTS (2023-2024)

6 CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 15 CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 EQUIPMENT
    • 6.2.1 INNOVATIVE PRODUCT LAUNCHES WITH IMPROVED DIAGNOSIS AND REAL-TIME MONITORING ABILITIES TO DRIVE MARKET
    • TABLE 16 CONTRAST-ENHANCED ULTRASOUND MARKET FOR EQUIPMENT, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 CONTRAST AGENTS
    • TABLE 17 CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 18 CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.1 MOLECULE-TARGETED MICROBUBBLES
      • 6.3.1.1 Rising use in targeted therapies to drive market
    • TABLE 19 CONTRAST-ENHANCED ULTRASOUND MARKET FOR MOLECULE-TARGETED MICROBUBBLES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.2 NANOPARTICLE MICROBUBBLES
      • 6.3.2.1 Utilization in thermal therapies to fuel market
    • TABLE 20 CONTRAST-ENHANCED ULTRASOUND MARKET FOR NANOPARTICLE MICROBUBBLES, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 SOFTWARE AND SERVICES
    • 6.4.1 RISING UTILIZATION OF SOFTWARE FOR OPTIMAL IMAGE VISUALIZATION TO DRIVE MARKET
    • TABLE 21 CONTRAST-ENHANCED ULTRASOUND MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 22 CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 DIAGNOSTIC APPLICATIONS
    • TABLE 23 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • 7.2.1 CARDIOLOGY
      • 7.2.1.1 Increasing incidence of CVD to drive market
    • TABLE 24 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2 HEPATIC
      • 7.2.2.1 Utilization of CEUS technology in characterization of focal liver lesions to drive market
    • TABLE 25 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC HEPATIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.3 NEPHROLOGY
      • 7.2.3.1 Ability to identify renal complications to propel market
    • TABLE 26 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC NEPHROLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.4 OTHER DIAGNOSTIC APPLICATIONS
    • TABLE 27 CONTRAST-ENHANCED ULTRASOUND MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 THERAPEUTIC APPLICATIONS
    • TABLE 28 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • 7.3.1 CARDIOLOGY
      • 7.3.1.1 Growing applications in targeted drug delivery to propel market
    • TABLE 29 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 7.3.2 VASCULAR
      • 7.3.2.1 Growing use of contrast agents in blood flow dynamics to fuel market
    • TABLE 30 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC VASCULAR APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 7.3.3 ONCOLOGY
      • 7.3.3.1 Rising utilization in targeted therapy to drive market
    • TABLE 31 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC ONCOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 7.3.4 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 32 CONTRAST-ENHANCED ULTRASOUND MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

8 CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 33 CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS AND SURGICAL CENTERS
    • 8.2.1 RISING NUMBER OF CEUS-BASED MEDICAL PROCEDURES TO DRIVE MARKET
    • TABLE 34 CONTRAST-ENHANCED ULTRASOUND MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 DIAGNOSTIC IMAGING CENTERS
    • 8.3.1 RISING ESTABLISHMENT OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
    • TABLE 35 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 AMBULATORY SURGERY CENTERS
    • 8.4.1 RISING VOLUME OF EMERGENCY SURGERIES TO PROPEL MARKET
    • TABLE 36 CONTRAST-ENHANCED ULTRASOUND MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER END USERS
    • TABLE 37 CONTRAST-ENHANCED ULTRASOUND MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

9 CONTRAST-ENHANCED ULTRASOUND MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 38 CONTRAST-ENHANCED ULTRASOUND MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET SNAPSHOT
    • 9.2.1 NORTH AMERICA: RECESSION IMPACT
    • TABLE 39 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 42 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 44 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 US
      • 9.2.2.1 High adoption rate of innovative medical technologies to drive market
    • TABLE 46 US: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 47 US: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.2.3 CANADA
      • 9.2.3.1 Increasing incidence of heart & kidney diseases to drive market
    • TABLE 48 CANADA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 49 CANADA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
  • 9.3 EUROPE
    • 9.3.1 EUROPE: RECESSION IMPACT
    • TABLE 50 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 53 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 55 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 56 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 GERMANY
      • 9.3.2.1 High healthcare expenditure to propel market
    • TABLE 57 GERMANY: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 58 GERMANY: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Rising target patient population and government-funded investments for advanced medical equipment to fuel uptake
    • TABLE 59 FRANCE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 60 FRANCE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.3.4 UK
      • 9.3.4.1 Increasing investments in diagnostic imaging to drive market
    • TABLE 61 UK: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 62 UK: CONTRAST-ENHANCED ULTRASOUND FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.3.5 REST OF EUROPE
    • TABLE 63 REST OF EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 64 REST OF EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET SNAPSHOT
    • 9.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 65 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Presence of universal healthcare reimbursement system to support market growth
    • TABLE 72 JAPAN: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 73 JAPAN: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.4.3 CHINA
      • 9.4.3.1 Rising government initiatives for improvements in healthcare infrastructure to drive market
    • TABLE 74 CHINA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 75 CHINA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.4.4 INDIA
      • 9.4.4.1 Growing public-private investments in novel medical technologies to drive market
    • TABLE 76 INDIA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 77 INDIA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 78 REST OF ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 79 REST OF ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
  • 9.5 REST OF THE WORLD
    • 9.5.1 REST OF THE WORLD: RECESSION IMPACT
    • TABLE 80 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 81 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 82 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 83 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021-2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 25 CONTRAST-ENHANCED ULTRASOUND MARKET: KEY PLAYER STRATEGIES
  • 10.3 REVENUE SHARE ANALYSIS
    • FIGURE 26 CONTRAST-ENHANCED ULTRASOUND MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS (2022)
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 27 CONTRAST-ENHANCED ULTRASOUND MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022)
    • TABLE 86 CONTRAST-ENHANCED ULTRASOUND MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 10.5 COMPANY EVALUATION MATRIX (2022)
    • 10.5.1 STARS
    • 10.5.2 PERVASIVE PLAYERS
    • 10.5.3 EMERGING LEADERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 28 CONTRAST-ENHANCED ULTRASOUND MARKET: COMPANY EVALUATION MATRIX (2022)
  • 10.6 COMPETITIVE BENCHMARKING
    • TABLE 87 CONTRAST-ENHANCED ULTRASOUND MARKET: PRODUCT & REGIONAL FOOTPRINT ANALYSIS
  • 10.7 COMPETITIVE SCENARIO AND TRENDS
    • 10.7.1 PRODUCT LAUNCHES
    • TABLE 88 CONTRAST-ENHANCED ULTRASOUND MARKET: PRODUCT LAUNCHES (JANUARY 2020-JULY 2023)
    • 10.7.2 DEALS
    • TABLE 89 CONTRAST-ENHANCED ULTRASOUND MARKET: DEALS (JANUARY 2020-JULY 2023)
    • 10.7.3 OTHER DEVELOPMENTS
    • TABLE 90 CONTRAST-ENHANCED ULTRASOUND MARKET: OTHER DEVELOPMENTS (JANUARY 2020-JULY 2023)

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 11.1.1 GE HEALTHCARE
    • TABLE 91 GE HEALTHCARE: COMPANY OVERVIEW
    • FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
    • 11.1.2 LANTHEUS
    • TABLE 92 LANTHEUS: COMPANY OVERVIEW
    • FIGURE 30 LANTHEUS: COMPANY SNAPSHOT (2022)
    • 11.1.3 BRACCO IMAGING S.P.A.
    • TABLE 93 BRACC0 IMAGING S.P.A.: COMPANY OVERVIEW
    • 11.1.4 KONINKLIJKE PHILIPS N.V.
    • TABLE 94 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
    • FIGURE 31 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
    • 11.1.5 SIEMENS HEALTHINEERS
    • TABLE 95 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
    • FIGURE 32 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022)
    • 11.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • TABLE 96 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
    • FIGURE 33 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
    • 11.1.7 CANON INC.
    • TABLE 97 CANON INC.: COMPANY OVERVIEW
    • FIGURE 34 CANON INC.: COMPANY SNAPSHOT (2022)
    • 11.1.8 ESAOTE S.P.A
    • TABLE 98 ESAOTE S.P.A: COMPANY OVERVIEW
    • 11.1.9 SAMSUNG ELECTRONICS CO., LTD.
    • TABLE 99 SAMSUNG ELECTRONICS CO., LTD.: COMPANY OVERVIEW
    • FIGURE 35 SAMSUNG ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
    • 11.1.10 GUERBET
    • TABLE 100 GUERBET: COMPANY OVERVIEW
    • FIGURE 36 GUERBET: COMPANY SNAPSHOT (2022)
  • 11.2 OTHER PLAYERS
    • 11.2.1 NANOPET PHARMA GMBH
    • 11.2.2 BAYER AG
    • 11.2.3 REVVITY
    • 11.2.4 SOLSTICE PHARMACEUTICALS B.V.
    • 11.2.5 TRIVITRON HEALTHCARE
    • 11.2.6 LERIVA
    • 11.2.7 JB PHARMA
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS